Clinical Trials
Several clinical trials are currently investigating melanin and skin pigmentation characteristics, targeting conditions such as generalized melanin pigmentation in pulse oximetry assessments, acanthosis nigricans-related hyperpigmentation, and skin laxity. Sponsored by academic and clinical institutions including the University of California San Diego, Huashan Hospital, Srinakharinwirot University, and Mahidol University, these Phase 3 and unclassified protocols are currently recruiting or enrolling by invitation. The interventions evaluated range from spectrophotometric calibration for pulse oximetry to light-emitting diode phototherapy and picosecond laser treatments.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06298422 | Enrolling by invitation | Generalised Melanin Pigmentation|Pulse Oximetry |
University of California San Diego |
2024-04-01 | -- |
| NCT06349447 | Recruiting | Hyperpigmentation |
Yanjun Dan|Huashan Hospital |
2024-04-10 | Not Applicable |
| NCT06213987 | Recruiting | Acanthosis Nigricans|Hyperpigmentation |
Srinakharinwirot University |
2024-02-01 | Phase 3 |
| NCT06231914 | Recruiting | Laxity; Skin |
Mahidol University |
2023-12-01 | Not Applicable |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).